COMPANY

US WorldMeds

HQ: Louisville, KY source · usworldmeds.com ↗ · Southeast

Location: Louisville, KY · source · Oct 14, 2026

Profile checked Oct 10, 2026

13NIH grants

NIH awards 13

Annual award amounts. Total $27.2M.

Jun 17, 2020 NIH award 5R01DA047690-03 FY2020: $800,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GULLO, KRISTEN LEANN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. Accelerated Development of Lofexidi source ↗
Jun 19, 2019 NIH award 5R01DA047690-02 FY2019: $2,330,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GULLO, KRISTEN LEANN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. Accelerated Development of Lofexi source ↗
Sep 19, 2018 NIH award 1R01DA047690-01 FY2018: $670,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI GULLO, KRISTEN LEANN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. Accelerated Development of Lofexidi source ↗
Mar 16, 2016 NIH award 3U01DA033276-03S1 FY2016: $813,971 awarded for that fiscal year; activity U01 (OTHER_NIH); PI GORODETZKY, CHARLES W.; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. NDA-Enabling Lofexidine Program source ↗
Jul 18, 2014 NIH award 3U01DA030916-03S2 FY2014: $1,438,532 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LONGSTRETH, JAMES ALVAN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. NDA-Enabling Phase I Lofexid source ↗
Jul 16, 2014 NIH award 5U01DA033276-03 FY2014: $5,967,600 awarded for that fiscal year; activity U01 (OTHER_NIH); PI GORODETZKY, CHARLES W.; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. A Phase 3, Double-Blind Efficac source ↗
Aug 29, 2013 NIH award 3U01DA030916-03S1 FY2013: $91,375 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LONGSTRETH, JAMES ALVAN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. NDA-Enabling Phase I Lofexidine source ↗
Aug 1, 2013 NIH award 5U01DA033276-02 FY2013: $5,544,365 awarded for that fiscal year; activity U01 (OTHER_NIH); PI GORODETZKY, CHARLES W.; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. A Phase 3, Double-Blind Efficac source ↗
Jan 31, 2013 NIH award 5U01DA030916-03 FY2013: $1,107,186 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LONGSTRETH, JAMES ALVAN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. NDA-Enabling Phase I Lofexidin source ↗
Sep 19, 2012 NIH award 1U01DA033276-01A1 FY2012: $5,982,000 awarded for that fiscal year; activity U01 (OTHER_NIH); PI GORODETZKY, CHARLES W.; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. A Phase 3, Double-Blind Effic source ↗
Jun 16, 2012 NIH award 3U01DA030916-02S1 FY2012: $468,517 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LONGSTRETH, JAMES ALVAN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. NDA-Enabling Phase I Lofexidin source ↗
Feb 24, 2012 NIH award 5U01DA030916-02 FY2012: $976,880 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LONGSTRETH, JAMES ALVAN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. NDA-Enabling Phase I Lofexidine source ↗
Feb 15, 2011 NIH award 1U01DA030916-01 FY2011: $999,244 awarded for that fiscal year; activity U01 (OTHER_NIH); PI LONGSTRETH, JAMES ALVAN; recipient as written: US WORLDMEDS, LLC, LOUISVILLE, KY. NDA-Enabling Phase I Lofexidine source ↗